175 related articles for article (PubMed ID: 3554371)
1. Regulation of microvascular prostacyclin and thromboxane with inhibitors of arachidonic acid metabolism.
Knight KR; Collopy PA; Martin TJ; O'Brien BM
Prostaglandins; 1987 Mar; 33(3):445-57. PubMed ID: 3554371
[TBL] [Abstract][Full Text] [Related]
2. Influence of selective thromboxane synthetase blocker CGS-13080 on thromboxane and prostacyclin biosynthesis in whole blood: evidence for synthesis of prostacyclin by leukocytes from platelet-derived endoperoxides.
Mehta J; Mehta P; Lawson DL; Ostrowski N; Brigmon L
J Lab Clin Med; 1985 Sep; 106(3):246-52. PubMed ID: 3928780
[TBL] [Abstract][Full Text] [Related]
3. Effects of a thromboxane synthetase inhibitor and a thromboxane antagonist on release and activity of thromboxane A2 and prostacyclin in vitro.
O'Keefe EH; Liu EC; Greenberg R; Ogletree ML
Prostaglandins; 1985 May; 29(5):785-97. PubMed ID: 3925501
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of arachidonic acid induced-aggregation of rabbit platelets with CV-4151 (isbogrel), a selective thromboxane A2 (TXA2) synthase inhibitor: modulation of the antiplatelet action and prostanoid metabolism by rat aortic rings.
Terashita Z; Imura Y; Nishikawa K
J Lipid Mediat Cell Signal; 1996 Jan; 13(1):1-8. PubMed ID: 8821806
[TBL] [Abstract][Full Text] [Related]
5. Effects of thromboxane synthetase inhibition on arachidonate metabolism and platelet behaviour.
Parry MJ
Br J Clin Pharmacol; 1983; 15 Suppl 1(Suppl 1):23S-29S. PubMed ID: 6401997
[TBL] [Abstract][Full Text] [Related]
6. Effects of flunixin meglumine, phenylbutazone and a selective thromboxane synthetase inhibitor (UK-38,485) on thromboxane and prostacyclin production in healthy horses.
Hardee MM; Moore JN; Hardee GE
Res Vet Sci; 1986 Mar; 40(2):152-6. PubMed ID: 3517992
[TBL] [Abstract][Full Text] [Related]
7. Potentiation by dazoxiben, a thromboxane synthetase inhibitor, of platelet aggregation inhibitory activity of a thromboxane receptor antagonist and of prostacyclin.
Bertele V; De Gaetano G
Eur J Pharmacol; 1982 Dec; 85(3-4):331-3. PubMed ID: 6295787
[TBL] [Abstract][Full Text] [Related]
8. Effect of ischemic skin flap elevation on tissue and plasma thromboxane A2 and prostacyclin production: modification by thromboxane synthetase inhibition.
Edstrom LE; Balkovich M; Slotman GJ
Ann Plast Surg; 1988 Feb; 20(2):106-11. PubMed ID: 3281544
[TBL] [Abstract][Full Text] [Related]
9. A selective inhibitor of thromboxane synthetase activity of rabbit heart tissue: a pyridazinic derivative.
Pham Huu Chanh ; Lasserre B; Pham Huu Chanh A; Palhares de Miranda AL; Tronche P; Couquelet J; Rubat C
Prostaglandins Leukot Essent Fatty Acids; 1988 Aug; 33(2):143-7. PubMed ID: 3140251
[TBL] [Abstract][Full Text] [Related]
10. Pathogenesis of cardiovascular disorders in streptozotocin-induced diabetes in rat. II. Correlation between lipid peroxides, thromboxane A2/prostacyclin, and platelet aggregation in different stages of diabetes.
Somova L; Kamenov V; Doncheva M; Kirilov G; Vassileva M
Acta Physiol Pharmacol Bulg; 1988; 14(3):57-62. PubMed ID: 3066112
[TBL] [Abstract][Full Text] [Related]
11. Pharmacologic modification of blood flow in the rabbit microvasculature with prostacyclin and related drugs.
Knight KR; Crabb DJ; Niall M; Angus JA; Martin TJ; O'Brien BM
Plast Reconstr Surg; 1985 May; 75(5):692-702. PubMed ID: 3157201
[TBL] [Abstract][Full Text] [Related]
12. Thromboxane and prostacyclin in acute lung injury caused by venous air emboli in unanesthetized sheep.
Bonsignore MR; Rice TR; Dodek PM; Staub NC
Microcirc Endothelium Lymphatics; 1986; 3(2):187-212. PubMed ID: 3295507
[TBL] [Abstract][Full Text] [Related]
13. Thromboxane synthase inhibitors suppress more effectively the aggregation of thromboxane receptor-desensitized than that of normal platelets: role of adenylylcyclase up-regulation.
Vezza R; Nenci GG; Gresele P
J Pharmacol Exp Ther; 1995 Dec; 275(3):1497-505. PubMed ID: 8531121
[TBL] [Abstract][Full Text] [Related]
14. A possible role of thromboxane A2 (TXA2) and prostacyclin (PGI2) in circulation.
Gryglewski RJ; Dembínska-Kieć A; Korbut R
Acta Biol Med Ger; 1978; 37(5-6):715-23. PubMed ID: 369254
[TBL] [Abstract][Full Text] [Related]
15. Response of the rabbit cutaneous microcirculation to prostanoid modifiers as determined by laser Doppler flowmetry.
Knight KR; Collopy PA; O'Brien BM
Microvasc Res; 1986 Mar; 31(2):197-202. PubMed ID: 3517597
[TBL] [Abstract][Full Text] [Related]
16. CV-4151--a potent, selective thromboxane A2 synthetase inhibitor.
Terashita Z; Imura Y; Tanabe M; Kawazoe K; Nishikawa K; Kato K; Terao S
Thromb Res; 1986 Jan; 41(2):223-37. PubMed ID: 3083523
[TBL] [Abstract][Full Text] [Related]
17. Effect of the infusion of OKY-046, a thromboxane A2 synthase inhibitor, on urinary metabolites of prostacyclin and thromboxane A2 in healthy human subjects.
Morio H; Hirai A; Terano T; Tamura Y; Yoshida S
Thromb Haemost; 1993 Mar; 69(3):276-81. PubMed ID: 8470052
[TBL] [Abstract][Full Text] [Related]
18. Thromboxane A2 accounts for bronchoconstriction but not for platelet sequestration and microvascular albumin exchanges induced by fMLP in the guinea pig lung.
Bureau MF; De Clerck F; Lefort J; Arreto CD; Vargaftig BB
J Pharmacol Exp Ther; 1992 Feb; 260(2):832-40. PubMed ID: 1738127
[TBL] [Abstract][Full Text] [Related]
19. Effect of thromboxane A2 synthetase inhibition, singly and combined with thromboxane A2/prostaglandin endoperoxide receptor antagonism, on inositol phospholipid turnover and on 5-HT release by washed human platelets.
de Chaffoy de Courcelles D; De Clerck F
Eur J Pharmacol; 1990 Mar; 188(2-3):161-9. PubMed ID: 2318257
[TBL] [Abstract][Full Text] [Related]
20. Effect of OKY-046, a thromboxane A2 synthetase inhibitor, on arachidonate-induced platelet aggregation: possible role of "prostaglandin H2 steal" mechanism.
Kuzuya T; Hoshida S; Yamagishi M; Ohmori M; Inoue M; Kamada T; Tada M
Jpn Circ J; 1986 Nov; 50(11):1071-8. PubMed ID: 3102802
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
